Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Current Assets: 2014-2025

Historic Current Assets for ImmunityBio (IBRX) over the last 11 years, with Sep 2025 value amounting to $329.5 million.

  • ImmunityBio's Current Assets rose 101.96% to $329.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $329.5 million, marking a year-over-year increase of 101.96%. This contributed to the annual value of $184.6 million for FY2024, which is 37.23% down from last year.
  • As of Q3 2025, ImmunityBio's Current Assets stood at $329.5 million, which was up 58.31% from $208.1 million recorded in Q2 2025.
  • ImmunityBio's 5-year Current Assets high stood at $334.3 million for Q4 2021, and its period low was $66.8 million during Q2 2023.
  • Moreover, its 3-year median value for Current Assets was $195.7 million (2024), whereas its average is $193.0 million.
  • Per our database at Business Quant, ImmunityBio's Current Assets plummeted by 57.95% in 2022 and then soared by 263.38% in 2024.
  • Over the past 5 years, ImmunityBio's Current Assets (Quarterly) stood at $334.3 million in 2021, then tumbled by 57.95% to $140.6 million in 2022, then surged by 109.20% to $294.1 million in 2023, then slumped by 37.23% to $184.6 million in 2024, then surged by 101.96% to $329.5 million in 2025.
  • Its Current Assets was $329.5 million in Q3 2025, compared to $208.1 million in Q2 2025 and $109.2 million in Q1 2025.